Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.41USD
4:00pm EDT
Change (% chg)

$-0.01 (-1.21%)
Prev Close
$0.42
Open
$0.43
Day's High
$0.44
Day's Low
$0.41
Volume
274,188
Avg. Vol
436,287
52-wk High
$3.08
52-wk Low
$0.40

Chart for

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.56
Market Cap(Mil.): $70.26
Shares Outstanding(Mil.): 162.44
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -1.32 -- --
ROI: -77.30 1.96 12.83
ROE: -102.28 1.12 14.95

BRIEF-Novartis Receives Health Canada Approval Of Its Car-T Cell Therapy, Kymriah I

* NOVARTIS RECEIVES HEALTH CANADA APPROVAL OF ITS CAR-T CELL THERAPY, KYMRIAH™ (TISAGENLECLEUCEL)I

Sep 06 2018

BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS

May 10 2018

BRIEF-Celldex Therapeutics Approves Workforce Reduction

* CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS

Apr 24 2018

Earnings vs. Estimates